Ciclopirox and cytarabine for the treatment of leukemic disorders
AssigneeUniversity Health Network
InventorsAaron D. Schimmer, Yanina Eberhard
Life of this patent
Estimating the term…
Abstract
The present application relates to compositions and methods for treating leukemic disorders. In particular, the present application relates to compositions and methods for treating the leukemic disorders such as acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) using ciclopirox and cytarabine.
Claims28
A method of treating a leukemic disorder comprising administering an effective amount of ciclopirox and an effective amount of cytarabine to a subject in need of such treatment.
5-7. (canceled)
(canceled)
14-15. (canceled)
A pharmaceutical composition for treatment of a leukemic disorder comprising an effective amount of ciclopirox, an effective amount of cytarabine and a pharmaceutically acceptable carrier in a dosage form, wherein said dosage form contains from about 20 mg to about 1000 mg of said ciclopirox and an effective amount of cytarabine, from about 40 mg to about 500 mg of said ciclopirox and an effective amount of cytarabine, an amount suitable to provide about 1 to about 200 mg of ciclopirox/kg body weight or an amount suitable to provide about 5 to about 50 mg of ciclopirox/kg body weight, formulated into a solid oral dosage form, a liquid dosage form or an injectable dosage.
(canceled)
19-21. (canceled)
25-27. (canceled)
29-33. (canceled)
A method of inhibiting survivin activity or levels comprising detecting increased activity or level of survivin in a leukemic disorder cell or population of leukemic disorder cells compared to a control;
- and contacting the cell or cells with ciclopirox and cytarabine, wherein the ciclopirox and cytarabine are contacted in a combined amount effective to decrease the activity or level of survivin.
Dependencies are inferred from the claim text.